MRKH

Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress

Retrieved on: 
Tuesday, May 9, 2023
HRD, Genomics, GAAP, Curie Institute (Paris), Doctor of Philosophy, Acquisition, Investment, Risk, DSM-IV codes, Bone marrow, University, NGS, Spectrum, Mosaic, Research, Whole genome sequencing, LRS, Children's Hospital Los Angeles, WGS, Growth, Hospital, OEM, OGM, NMPA, Trisomy, Total, BGPT, MRKH, DNA, Workflow, Cancer, SOC, Publication, Genetic disorder, Standard of care, University of Toronto, ASD, SAN, National Medical Products Administration, IVD, MD Anderson Cancer Center, Acceleration, Toronto, SVS, Sale, NVIDIA, Female, Breast cancer, Mobile phone, Video game, Medical device, Pharmaceutical industry, Dietary supplement, Renewable energy, Augusta University

GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022.

Key Points: 
  • GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022.
  • First quarter 2023 non-GAAP¹ gross margin was 30%, compared to 15% from the first quarter of 2022.
  • First quarter 2023 GAAP operating expense was $39.9 million, compared to $30.8 million in the first quarter of 2022.
  • First quarter 2023 non-GAAP operating expense was $33.6 million, compared to $24.2 million in the first quarter of 2022.

Bionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females

Retrieved on: 
Wednesday, March 22, 2023
Vagina, Pregnancy, FISH, CMA, Augusta University, Genomics, Parent, KT, SVS, Mosaic, Research, Doctor of Philosophy, Uterus, Disorder, SV, Karyotype, CNV, Chromosomal translocation, Patient, SNP, Fertility, OGM, Gene, Syndrome, PCR, Trisomy, Female, Disease, Pharmaceutical industry, Microscope, Birth control, Medical imaging, Vaccine, Agriculture, MRKH

MRKH is one of several forms of Müllerian agenesis, a disorder that affects 1 in 4,500 females and impacts patients’ reproductive systems and potential ability to carry a pregnancy.

Key Points: 
  • MRKH is one of several forms of Müllerian agenesis, a disorder that affects 1 in 4,500 females and impacts patients’ reproductive systems and potential ability to carry a pregnancy.
  • Molecular diagnosis is helpful in determining the best treatment for MRKH, but because genetic causes are largely unknown, research into this prevalent class of disorders is key to enabling effective therapies.
  • In this study, researchers used OGM to analyze MRKH samples to detect a variety of SVs that may be relevant to MRKH’s genetic etiology in a single assay.
  • We believe the authors’ findings that indicate mosaicism, including for a trisomy 12, could be involved in the pathogenesis of MRKH were particularly significant,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.